Review of patient-derived cancer organoids on drug-sensitivity prediction from the aspect of clinical oncotherapy

Key Points

• The aim is to evaluate the effectiveness of patient-derived organoids in predicting drug sensitivity across various cancer types and treatment strategies.
• Systematic literature review of patient-derived organoid applications in drug sensitivity testing.
• Analysis of different tumor types, clinical stages, and therapies, focusing on late-stage patients.
• Evaluation of predictive accuracy and sensitivity of drug testing results.
• Overall predictive accuracy of PDOs in drug sensitivity testing is approximately 80%.
• Late-stage cancer patients exhibit higher negative predictive values.
• Significant heterogeneity in drug response observed among different cancer types and drug classes linked to mutations in key driver genes.